Enhanced Curcumin Compositions for Neurological Disorders

This inventive concept relates to improved curcumin compositions and methods for treating neurological disorders, enhancing the original patent's limitations by increasing bioavailability, brain penetration, and efficacy while improving stability and shelf life.

The original patent disclosed curcumin compositions as NK3 antagonists, but these compositions had limitations in terms of bioavailability, brain penetration, and efficacy. The new inventive concept addresses these limitations by introducing novel formulations, delivery systems, and compositions that overcome the existing drawbacks.

The new inventive concept comprises four main aspects: 1) a method for treating neurological disorders using a curcumin composition with improved bioavailability, 2) a system for delivering curcumin compositions to the brain using nanoparticle formulations, 3) a curcumin composition with a synergistic ratio of diferuloylmethane to demethoxycurcumin to bis-demethoxycurcumin, and 4) a method for preparing curcumin compositions with improved stability and shelf life using liposome encapsulation. These aspects work in tandem to provide a more effective and efficient treatment for neurological disorders.

The new claims introduce novel formulations, delivery systems, and compositions that significantly improve the original patent's limitations, providing a non-obvious solution to the existing drawbacks. The inventive concept's novelty lies in the specific combinations of components, ratios, and formulations that achieve the desired enhancements.

Alternative embodiments of the inventive concept may include different nanoparticle formulations, varying synergistic ratios, and diverse liposome encapsulation methods. These variations can be tailored to specific neurological disorders, patient populations, or treatment regimens, ensuring broad conceptual coverage.

The enhanced curcumin compositions and methods have significant commercial potential in the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and depression. The target market includes pharmaceutical companies, biotechnology firms, and healthcare providers seeking more effective and efficient treatments for these disorders.